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Opinion statement
Afterapatienthasinitiatedanantiepilepticdrug(AED)andachievedasustainedperiodof
seizure freedom, the bias towards continuing therapy indefinitely can be substantial.
StudiesshowthattherateofseizurerecurrenceafterAEDwithdrawalisabouttwotothree
timestherateinpatientswhocontinueAEDs,buttherearemanybenefitstoAEDwithdrawal
thatshouldbeevaluatedonanindividualizedbasis.AEDdiscontinuationmaybeconsidered
inpatientswhoseseizureshavebeencompletelycontrolledforaprolongedperiod,typically
1 to 2 years for children and 2 to 5 years for adults. For children, symptomatic epilepsy,
adolescent onset, and a longer time to achieve seizure control are associated with a worse
prognosis.In adults,factors suchasa longerdurationofepilepsy,anabnormalneurologic
examination, an abnormal EEG, and certain epilepsy syndromes are known to increase the
riskofrecurrence.Eveninpatientswitha favorable prognosis,however,the riskofrelapse
can be as high as 20% to 25%. Before withdrawing AEDs, patients should be counseled
abouttheir individualriskfor relapse andthepotential implicationsofarecurrentseizure,
particularly for safety and driving.
Introduction
After a patient experiences a seizure, there is a natural
inclinationtointervene.Althoughanumberofvariables
influence the decision to start an antiepileptic drug
(AED), a strong desire to prevent further seizures often
tips the balance in favor of a medication. The next
question faced by both the patient and the physician is
the length oftimethat treatment isneeded. Unlikeother
medical therapies, which may have well-defined dura-
tions, the required duration of antiepileptic therapy is
muchlessconcreteandremainssomewhatcontroversial.
This review explores the literature related to the
withdrawal of AEDs, focusing on studies and reviews
of epilepsy patients who have experienced a prolonged
period of seizure freedom. With rare exception,
patients who continue to experience seizures require
continued therapy. For patients who have entered a
period of seizure remission, however, decision-making
is more uncertain; AED therapy may have prevented a
recurrence of seizures in some patients, but others may
have entered a period of seizure remission regardless
of therapy. Thus, it is the physician’s responsibility
toweightherisksandbenefitsofcontinuedAEDtherapy
on an individualized basis. This review discusses the
factors to be considered in making this decision.
Deciding to Initiate an AED
Although this review focuses on the decision to with-
draw an AED after a seizure-free interval, it is important
to acknowledge a number of studies and reviews thathave addressed the question of starting therapy
[1,2,3,4,5,6,7,8,9]. After two unprovoked seizures, the
risk of recurrence is relatively high [2], a diagnosis of ep-
ilepsy is made, and the accepted practice is to initiate an
AED. Instituting medical therapy after a single unpro-
voked seizure event is more controversial. Many studies
have examined this issue [1,2,4,6,7,8]. Across studies
designed as randomized, controlled trials, observational
analyses, and meta-analyses, seizure recurrence rates in
untreated patients range from 39% to 51% [1,2,6,7]a t
a2-yearfollowup.Insomecases,these datamaynotjus-
tify immediate treatment, but other studies have looked
at variables that increase the risk of recurrence [7,8,10].
Abnormalities on routine EEG testing and/or symptom-
atic causes of epilepsy, usually identified by brain imag-
ing, increase the risk of seizure recurrence [8]; these are
important considerations when deciding to initiate anti-
epileptic therapy.
Regardlessofthe oddsofseizure recurrence,the deci-
sion to initiate treatment is ultimately an individualized
matter. Variables such as work status, dependence on
driving, comorbid medical conditions, and concerns
aboutmedicationsideeffectsandidiosyncraticreactions
all play an important role in tailoring a decision for a
particular patient.
Deciding to Discontinue an AED
The decision to discontinue treatment with an AED
requires consideration of the same variables taken into
account in deciding to start treatment. The patient
plays a key role in this decision-making. Some patients
are willing to stop AEDs even when the risk of relapse
is substantial, whereas others fear the effects of seizure
recurrence on quality of life and opt to continue AEDs.
With the publication of the landmark Kwan and
Brodie study [11], physicians recognized that approx-
imately two thirds of epilepsy patients could achieve
seizure freedom when treated with an appropriately
chosen AED.Though these dataare certainly favorable
for most patients with new-onset epilepsy, they lead
to a difficult question for some: After achieving sei-
zure remission, is it appropriate to withdraw AED
therapy?
As one may expect, there is no definitive answer.
Important historical and recent studies provide some
data to guide an approach to this question, but ulti-
mately, population-based odds of recurrence serve only
as a starting point for each individual’s situation. Most
patients do not fit perfectly into a study population, so
multiple unique variables relevant to the individual
must be carefully considered.
ThequestionofwithdrawingAEDsafteraseizure-free
interval has been debated for many years. A 1994 meta-
analysisbyBergandShinnar[12,ClassIV]demonstrated
relapse risks of 25% at 1 year and 29% at 2 years after
AED discontinuation. Most studies have examined
patientswhowereseizure-freeforperiodsof2or4years.
Recurrence of seizures in these populations seemed to
occur relatively soon after AED discontinuation, with
about half of recurrences occurring within 6 months.
T h ee n t i r er e c u r r e n c er i s kd u et od i s c o n t i n u a t i o nw a s
seen within the first 2 years.
In 1996, the American Academy of Neurology
(AAN) recognized the importance of this frequent
clinical dilemma and issued a practice parameter
[13]. Using a system of evidence classification, the
parameter identified 17 studies for inclusion, although
only one study met the class I requirements of a ran-
domized controlled trial [14]. The parameter further
divided the included studies into categories examining
children versus adults. The seizure recurrence rates af-
ter AED discontinuation were then reported as pooled,
weighted averages: 31.2% for children and 39.4% for
adults [13]. Using data from all the included studies,
the authors also identified several variables that sug-
gested a greater chance of AED withdrawal without re-
lapse: a seizure-free period on AEDs of 2 to 5 years, a
single reported seizure type, a normal neurologic exam
and IQ, and a normalized EEG with treatment. The
guideline concluded that both pediatric and adult
epilepsy patients with these characteristics should
be offered the option of discontinuing antiepileptic
therapy [13].
Adult Studies The AAN practice parameter also high-
lighted the need for more randomized, double-blind,
controlled prospective trials to better assess this situa-
tion. At that time, only one unblinded randomized
controlledtrialhadbeenconductedintheadultepilepsy
population. This study, conducted by the Medical
Research Council [MRC] Antiepileptic Drug Withdrawal
Study Group, and was published in 1991 [14,Class II].
The primary criterion for inclusion was a seizure-freepe-
riodof2yearsonAEDs,and1013patientswererandom-
ized to either continued drug treatment or a slow
withdrawal over 6 months. At 2 years of follow-up, the
continued-treatment group had a relapse rate of 22%,
compared with a relapse rate of 41% in the withdrawal
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withdrawal divided by the seizure recurrence rate with
continuation) peaked at 9 months and continued to
demonstrate a higher risk in the withdrawal group at
2 years. After 2 years of follow-up, however, the hazard
ratio inverted, and the withdrawal group no longer
exhibited a higher rate of recurrence.
In 2002, Specchio and colleagues [15,C l a s sI I ]
published another prospective study of 330 epilepsy
patients who had been seizure-free on monotherapy
for at least 2 years. These patients were not random-
ized but were divided into two cohorts based on those
who chose a drug withdrawal option. Those patients
who entered the discontinuation arm had their medica-
tion tapered over a 3-month period. The continued-
treatment cohort had a relapse rate of 28%, compared
with a rate of 50% for the withdrawal cohort. Mean fol-
low-up times were 48.0 months for the continuation
group and 46.6 months for the withdrawal group. Over-
all,thisstudyreportedaseizurerelapseriskinthediscon-
tinuation group that was 2.9 times that of the treated
group, even after accounting for prognostic factors.
Aktekin and colleagues [16, Class III] published an-
other prospective but unrandomized study in 2006,
exploring the seizure relapse rate in adult patients
who had been seizure-free for at least 4 years. The dis-
continuation program eventually enrolled 49 patients,
with medication being tapered by one sixth every
2 months. Follow-up was 36 months, during which
the risk of seizure relapse was 52%. The highest rate
of relapse occurred early in the drug withdrawal period
[16].
In 2008, Lossius and colleagues [17￿,Class I] pub-
lished the first randomized, double-blind, controlled
trial of AED withdrawal in adult epilepsy patients
who had been seizure-free for at least 2 years. In this
study, 79 patients were randomized to drug withdraw-
al, and 81 patients entered the drug continuation arm.
Both groups were observed for at least 12 months or
until seizure relapse. The authors reported a seizure
relapse rate of 15% in the AED withdrawal group,
compared with 7% for the drug continuation group.
Further follow-up to a mean of 41 months revealed
a relapse rate of 27% in those patients who discontin-
ued therapy; unfortunately, this longer-term relapse
rate cannot be compared with a rate in the continua-
tion group because many of those patients chose to
withdraw from medications at the end of the blinded
period. Additionally, it is worth noting that potential
bias was introduced in this study because it did not in-
clude patients with a known higher risk of relapse,
such as those with idiopathic generalized epilepsy,
epileptiform discharges on EEG, or polytherapy [18].
Factors to Consider in Adults These studies all confirm
an increased risk of seizure recurrence following AED
withdrawal, even after a period of seizure freedom.
For some patients, this may be a risk worth taking.
Some special factors may further increase the risk of re-
currence, however, and this information should be
presented to patients who are considering drug with-
drawal. Several reviews of AED withdrawal have iden-
tified a number of factors associated with increased
risk: an abnormal neurologic examination, IQ less
than 70, longer duration of epilepsy, higher number
of seizures, multiple seizure types, focal epileptiform
abnormalities on EEG, and worsening EEG patterns af-
ter AED discontinuation [9,19]. Multiple studies have
shown that longer duration of disease and earlier age
of onset prior to the period of seizure freedom increase
recurrence risk [13,14,15,16]. The MRC study [14]
found that a higher risk of recurrence is correlated with
both the prior use of multiple AEDs and generalized
tonic-clonic seizure types. Certain epilepsy syndromes,
such as juvenile myoclonic epilepsy, are also known to
be associated with a higher relapse risk [19]. The ran-
domized controlled trial by Lossius et al. [17￿,Class I]
linked a normal neurologic examination and a history
of carbamazepine use with a lower risk of seizure re-
currence, but it should be noted again that this study
excluded many patients likely to be at higher risk
based on some of the factors listed above.
Some studies have also explored the impact of test-
ing results on the likelihood of a seizure recurrence.
Several studies have shown that EEG abnormalities
at the time of drug discontinuation increase the risk
of relapse in adults [15,20], and this association also
has been well demonstrated in the pediatric popula-
tion [19]. However, the trial by Lossius et al. [17￿,
Class I] did not find any prognostic correlation with
abnormal or epileptiform EEG studies, although this
study did not include certain epilepsy syndromes with
specific EEG patterns. In addition to EEG abnormalities,
focal findings on MRI, such as hippocampal pathology,
havebeenassociatedwithanincreasedriskofrecurrence
during drug withdrawal [21].
Pediatric Studies In the pediatric epilepsy population,
there are special considerations involved in the deci-
436 Epilepsysion to discontinue medications, and these patients
are often appropriately studied separately from adults.
Thenaturalcourseofsomepediatricepilepsysyndromes
is remission, regardless of treatment [22]. The original
practice parameter published by the AAN demonstrated
a slightly lower seizure relapse rate in the pediatric
population (31%) than in adults (39%) [13].
A 1998 study by Peters et al. [23, Class I] represents
a true prospective, randomized controlled trial for
AED withdrawal in the pediatric epilepsy population.
In this study, children who had achieved seizure
freedom on medications were randomized to drug
withdrawal after 6 or 12 seizure-free months. The
6-month cohort experienced a relapse rate of 55%,
compared with 49% for the longer-treatment cohort.
The magnitude of these relapse rates is consistent
with the findings of the MRC randomized trial
[14], as well as with more recent prospective with-
drawal trials focusing on the pediatric population
[24,25,26,27,28,29,30]. As with adults, the data are
relatively conclusive in showing that AED withdrawal
is associated with a substantially increased risk of sei-
zure recurrence, especially earlier in the time course
after the discontinuation.
Factors to Consider in Children As with the adult epi-
lepsy population, a number of variables must be
considered for any individual child who has entered a
seizure-freeperiod.Therelationshipbetweenthenumber
ofyears of seizure freedom and the relapse rateremains a
controversialarea.TheoriginalMRCstudy[14]suggested
that the longer the period of seizure freedom before
AEDwithdrawal,thegreaterthechancesofavoidingasei-
zure recurrence. This study pertained largely to adults,
however, and other studies in the pediatric population
have not demonstrated such a clear correlation [22,25,
27]. In a 2008 review, Camfield and Camfield [22]
recommended a seizure-free period of 1 to 2 years as an
acceptable length of time to justify an AED withdrawal
trial in the pediatric epilepsy population.
Perhaps more than in adult population, a child’s
epilepsy syndrome may also play an important role
in the decision to withdraw AEDs. Several pediatric
epilepsy syndromes are known to naturally reach a pe-
riod of remission in all cases, whereas others have a
more uncertain prognosis [31]. About 10% of child-
hood epilepsy syndromes, including syndromes such
as juvenile myoclonic epilepsy and reading epilepsy,
will never remit, and thus an AED withdrawal trial
would not be advisable, even after a period of seizure
freedom [22]. Syndromes with an intermediate prog-
nosis include the localization-related epilepsies, which
have been shown to have a higher risk of recurrence
in multiple studies [23,24,26,28,30]. However, a
diagnosis of localization-related epilepsy should not
uniformly prevent an AED withdrawal trial in seizure-
free pediatric patients.
Other factors that have been associated with a
higher relapse risk include adolescent age of onset
[12,25], a symptomatic etiology [12,28,30], an
abnormal neurologic examination [19,25], and an
epileptiform EEG pattern before or after withdrawal
[12,23,29,32]. An early response to the initial AED
therapy has been associated with a lower risk of
seizure recurrence [12,19].
Risks and Benefits of AED Withdrawal
The decision to attempt an AED withdrawal does not
depend exclusively on the risk of recurrence. For
patients who have achieved seizure freedom with ther-
apy, the primary consideration is a careful weighing of
the risks and benefits of the medical therapy. The idi-
osyncratic reactions to AEDs and their short-term and
long-term adverse effects are well known. Limiting
these effects is highly desirable. To varying degrees,
all AEDs can cause symptoms affecting quality of life,
such as drowsiness, fatigue, and inattention [33].
Additionally, older AEDs with effects of hepatic en-
zyme induction or inhibition can prove particularly
undesirable for patients taking multiple medications
for other conditions.
Several studies have documented improved out-
comes on common neuropsychiatric batteries and
mood assessment scales following AED discontinua-
tion [34,35,36], further validating concerns about the
impact of AED therapy on quality of life. Medications
may lead patients to perform less efficiently at work
and at home. Finally, there is also a certain stigma
attached to needing daily medications. If a medication
may not be necessary, it is reasonable—and perhaps
even requisite—to offer the patient a trial of medica-
tion withdrawal.
Of course, there are also substantial risks associated
with AED withdrawal. The obvious and substantial
risk that is highlighted in this review is the likelihood
of a seizure recurrence. However, it is important to
broaden the discussion of this possibility to consider
the implications of a relapse. Once a patient has expe-
rienced seizure recurrence, is there a risk that the prior
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other way, does the patient risk developing a medical-
ly intractable epilepsy after AED withdrawal? Evidence
suggests that this is usually not the case. In 2005,
Camfield and Camfield [27] reported a prospective
childhood epilepsy study that followed patients who
had become seizure-free and appropriately attempted
drug withdrawal. In their study population, 29% had
a seizure recurrence that required the reintroduction
of medications, and 97% of these patients regained
control. Of the entire cohort being followed, less than
1% developed medically resistant epilepsy after a trial
of AED withdrawal.
Studies in adults have been less clear, and a signif-
icant number of patients with medically intractable
epilepsy retrospectively report a prolonged period of
seizure freedom in their past. This situation raises
the concern of being “fooled” into attempting AED
withdrawal. A 2005 review of uncontrolled epilepsy
after a withdrawal trial cites a mean of 19% of patients
developing medically resistant epilepsy [37]. The risk
factors associatedwithahigherlikelihoodofthisscenar-
io were localization-related epilepsy, a symptomatic
etiology, and an abnormal neurologic examination.
TheauthorsofthisreviewcautionedagainstAEDdiscon-
tinuation in the adult population, especially when these
known risk factors are present.
The potential for death from a seizure or a seizure-
related event is another concern associated with re-
lapse. Status epilepticus and sudden unexplained
death in epilepsy (SUDEP) are the most serious com-
plications directly related to a seizure. In multiple
studies of both pediatric and adult populations, the
occurrence of seizure-related fatalities is very low
[22] and should not be emphasized in the decision
to attempt an AED withdrawal.
Much more likely than the development of intrac-
table epilepsy or death from seizure relapse are nega-
tive psychological effectsa n de f f e c t so nq u a l i t yo f
life. These are certainly important considerations be-
fore AED withdrawal. After adjusting to seizure con-
trol, a patient may suffer a significant psychological
setbackbecauseofarecurrence.Drivingandoccupation-
al duties are often affected by a relapse even if seizure
control is rapidly regained; the impact on quality of life
may thus be dramatic. For many patients, the mere pos-
sibility of such an event is enough to prevent them from
attempting an AED withdrawal.
Additionally, the discontinuation of some AEDs
may actually worsen psychological or neurologic func-
tioning, particularly in patients who suffer from psy-
chiatric or other comorbidities. Medications such as
valproic acid and lamotrigine are also indicated for
mood stabilization in patients with bipolar disorder,
and topiramate is commonly used in managing head-
ache disorders. Thus, it is important to consider the
full ramifications of a withdrawal trial for epilepsy
patients with certain comorbidities.
Treatment
When to withdraw
& Once a patient has entered a seizure-free interval and the possibility
of withdrawing medication is considered, it is vital to discuss the
appropriate time to initiate the withdrawal and the mechanism for
doing so. Unfortunately, there is no clear consensus on these topics
for either adults or children. Withdrawal studies in children have
quoted optimum seizure-free periods of 1 to 2 years [12], but some
of the studies on which these data are based have methodologic
shortcomings. Nonetheless, the Camfield and Camfield discussion
piece in 2008 [22] asserts that a seizure remission period of 2 years is
reasonable before attempting a drug withdrawal in children.
& The authors of a Cochrane review published in 2010 (re-analyzed
after a similar 2001 review) took a systematic approach to this issue,
searching for randomized controlled trials that addressed the length
of seizure remission [38￿]. The objective of the review was to
compare relapse risk after early (G2 years) and late (92 years) AED
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lyzed seven controlled trials, determining that the evidence supports
a seizure-free period of 2 years before attempting a discontinuation
trial in children [38￿]. In this review, the authors also found that
localization-related epilepsy or an abnormal EEG predicted a higher
rate of relapse in those patients who attempted an early drug
withdrawal.
& In this same Cochrane review, the authors found no eligible trials
that examined seizure-free adults, further validating the need for
further research in this area. The original AAN practice parameter
from 1996 suggested a wide range of 2 to 5 years of seizure freedom
prior to a withdrawal trial [13], and the MRC study [14] required a
period of at least 2 years’ remission for entry into the study. The 2008
review by Camfield and Camfield [22] suggests at least a 4-year
window of seizure remission for adults. These conclusions are based
on less rigorous (often retrospective) analyses in adults; it is most
accurate to state that evidence is lacking in this area. There are no
data supporting the withdrawal of AEDs prior to 2 years of remission
in adults.
How to withdraw
& Relatively few studies have focused on the mechanism for with-
drawing AEDs. The choice is between a relatively rapid taper period
or a slow taper period. Intuitively, it is inappropriate to abruptly
discontinue any AED because of an increased risk of withdrawal
seizures or even status epilepticus. This principle is particularly true
for benzodiazepines and barbiturates. Beyond this recommendation,
there is little evidence to support a particular style of medication
withdrawal.
& In the 2010 Cochrane review [38￿,Class I], the range of tapering
period for pediatric studies was from 4 weeks to 1 year. A 1994 study
compared withdrawal tapers of 6 weeks and 9 months in children
with epilepsy, finding no difference in seizure recurrence [24]. More
recently, a 2005 paper reported the results of a prospective,
randomized trial of medication taper periods of 1 month versus
6 months in children; there was no difference between the two
methods in the overall seizure recurrence rate [39].
& For adult epilepsy patients, there is little evidence to guide practice in
this area. In 2006, a Cochrane review attempted to identify
controlled trials in adults that addressed the question of tapering
speed [40]. The authors defined a “slow” taper as occurring over
more than 3 months, whereas a “rapid” taper was defined as
occurring within 3 months or less. Unfortunately, the authors could
identify no adult studies that met their methodologic criteria, further
highlighting the lack of evidence in this area. In the absence of
definitive data, quality-of-life and safety issues may favor relatively
rapid withdrawal (1–3 months). Because most seizures occur in the
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schedule extends the maximal “at risk” period for relapse, during
which the patient may need to restrict activities such as driving or
working around equipment with moving parts.
Special populations
& The population of epilepsy patients who have undergone surgical
resection deserves special mention regarding the decision to discon-
tinue AEDs. For patients who achieve a prolonged period of seizure
remission after epilepsy surgery, the standard of care can vary widely,
but many physicians apply the same 2-year requirement for this
group [41]. A 2004 study published by McIntosh et al. [42,Class IV]
supports this practice to some extent; their study followed 325
temporal lobectomy patients for as long as 10 years. They demon-
strated that the rate of seizure freedom declined over this length of
follow-up, but the discontinuation of AEDs after 2 years of remission
was not correlated with the increased recurrence. In 2006, a study by
Berg and colleagues [43,Class IV] showed similar results in a group of
postsurgical patients who had been seizure-free for at least 1 year.
Again, although the risk of seizure recurrence increased over the
length of follow-up, the evidence showed that this risk was
independent of whether AEDs were withdrawn. In 2009, Kerling et
al. [44,Class II] published a prospective, randomized study of post-
surgical patients who were seizure-free for 1 year; this study also
detected no differences in the rate of recurrence. These studies fully
support the practice of undergoing a withdrawal trial after 1 to
2 years of seizure remission following surgery.
& As with patients who have not undergone epilepsy surgery, there are
certain factors that elevate the recurrence risk in patients after surgery.
Several studies have demonstrated an increased risk in patients with a
longer duration of epilepsy, a history of secondarily generalized
seizures, and an absence of brain pathologic findings [42,43,44,45].
Patients with identifiable hippocampal sclerosis or other known
lesions have a greater chance of successfully maintaining seizure
freedom after surgery [42]. Patients who underwent neocortical
resections have been shown to do worse than those undergoing
standard anterior temporal lobectomy [46,47], but some of those
patients have successfully withdrawn from medications [46].
& In a 2008 commentary, Cole and Wiebe [48￿,Class IV] discussed the
true nature of the evidence supporting the practice of AED with-
drawal in postsurgical patients. After conducting a literature search,
they applied the same criteria for level of evidence that were used by
the AAN. Of 24 identified studies relevant to the issue, none reached
a level of evidence greater than class IV, which would not justify
clinical recommendation by the AAN standards. This situation
highlights the need for further research in this area, but it should not
necessarily prevent patients from attempting AED withdrawal trials.
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